Slate Medicines UK Secures £5.9m for Migraine Treatment Research

New therapeutics for migraine and headache disorders are the primary focus of Slate Medicines UK Limited, which has raised an estimated £5.9m in its latest funding round. The Altrincham-based company is developing a lead program centered on a monoclonal antibody that targets PACAP, a peptide involved in the physiology of migraine.

The company was incorporated in February 2026 and operates within the research and experimental development sector for natural sciences and engineering. This funding round, which was documented in filings during April, follows the company's recent establishment. The estimated £5.9m capital injection provides the resources necessary for the early-stage development of its therapeutic pipeline.

Neil George Buckley was appointed as a director of the company in February 2026, coinciding with the firm's incorporation. As a recently formed entity, Slate Medicines UK Limited has not yet published full financial metrics such as annual revenue, profit and loss statements, or total asset values.

The company's work addresses the medical need for more effective treatments for chronic headache conditions. By targeting PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide), the firm joins a specific area of biotechnological research aimed at blocking the pathways that trigger migraine attacks. This round represents the first major capital event for the business since its founding earlier this year.